Evidence map›Paper›PMID 42192975›Full record

ArticleCancers2026

Centralized Homologous Recombination Repair Testing in Metastatic Castration-Resistant Prostate Cancer: Real-World Data from a Multicenter Spanish Precision Oncology Program.

Belén Caramelo, Pilar García-Berbel, Sofia Del Carmen, Adriana Calapaqui, Luiz Corrêa, Lucia Martinez-Villaseñor, Marta Sotelo, Federico Rojo, Javier Gómez-Román, Ignacio Duran and 1 more

Abstract read
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Belén CarameloMedical Oncology Department, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.ORCID 0000-0002-9224-252X
Pilar García-BerbelInstituto de Investigación Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.
Sofia Del CarmenInstituto de Investigación Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.ORCID 0000-0001-9565-2009
Adriana CalapaquiInstituto de Investigación Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.ORCID 0000-0001-7748-1955
Luiz CorrêaDiagnostic Data Hub-DXD Hub, 08780 Barcelona, Spain.
Lucia Martinez-VillaseñorFaculty of Medicine, Catholic University of Valencia San Vicente Mártir, 46001 Valencia, Spain.
Marta SoteloMedical Oncology Department, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.
Federico RojoPathology Department, Fundación Jiménez Díaz, 28040 Madrid, Spain.ORCID 0000-0001-9989-0290
Javier Gómez-RománInstituto de Investigación Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.ORCID 0000-0002-2849-9435
Ignacio DuranMedical Oncology Department, Hospital Universitario Marqués de Valdecilla, 39008 Santander, Spain.ORCID 0000-0001-8571-7163
Javier FreireInstituto de Investigación Marqués de Valdecilla-IDIVAL, 39008 Santander, Spain.ORCID 0009-0002-4168-7163

Funding

AstraZeneca (Spain) ES-2023-6672
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

BRCAhomologous recombination repairPARP inhibitorprostate cancer

Identifiers

PMID42192975
PMCPMC13204402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.